Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

FMT+ QL1706+ bevacizumab+ Xelox som första linjebehandling för avancerad koloncancer av MSS-typ med levermetastas

22 september 2026 uppdaterad av: Hua Jiang

Fekal mikrobiota-transplantation i kombination med QL1706, bevacizumab och Xelox som första linjebehandling för avancerad koloncancer av MSS-typ med levermetastas: studieprotokoll för ett prospektivt, multi-centrum, enarmade fas II-undersökningstudie

The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 30 patients with advanced colorectal cancer patients with liver metastasis who have not received prior treatment. This study plans to reconstruct intestinal microecology through fecal microbiota transplantation (FMT), and combine with QL1706+Bevacizumab+XELOX to enhance the anti-tumor immune effect at the same time, thereby improving the prognosis of colorectal cancer patients with liver metastasis.

Studieöversikt

Status

Rekrytering

Detaljerad beskrivning

This is a prospective, single-arm, multi-center, exploratory clinical study. Patients with previously untreated, newly diagnosed advanced colorectal cancer with liver metastasis, who could be diagnosed by histological or cytological means, ECOG PS 0-1, excluded Ras, Raf wild type left colon/rectum, excluded dMMR/MSI-H. Eligible subjects who met the inclusion criteria were screened and signed informed consent.

FMT was performed 2 days after treatment with bevacizumab, and chemotherapy. QL1706, bevacizumab, and chemotherapy (XELOX) were administered every 3 weeks according to the patient's body surface area. A total of 6 cycles were performed. Subsequent maintenance therapy was at the discretion of the investigator.

RECIST v1.1 was used for tumor evaluation every 6 weeks during treatment. NCI-CTCAE 5.0 was used for safety assessment every 3 weeks. Adverse events were recorded throughout the study to 90 days after the end of treatment. Treatment continues until disease progression, subject withdraws informed consent, loss of follow-up, or death. Patients should provide 10ml whole blood samples and fecal samples at baseline, after two cycles of treatment, after four cycles of treatment, before maintenance treatment for the detection of efficacy prediction markers (each cycle is 21 days).

Studietyp

Interventionell

Inskrivning (Beräknad)

30

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Changzhou, Kina
        • Rekrytering
        • The Second People's Hospital of Changzhou
        • Kontakt:
          • Hua Jiang MD
          • Telefonnummer: +86-18015852711

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Histological or cytological confirmed advanced colorectal cancer with liver metastasis.
  2. Signed written informed consent.
  3. Have not received anti-tumor treatment.
  4. According to the investigators assessment, at least one measurable target lesion defined by RECIST v1.1.
  5. Patients of both sexes, aged ≥18 years and ≤75 years.
  6. ECOG PS 0-1;
  7. Expected survival time ≥ 3 months;
  8. Have adequate organ and bone marrow function, laboratory examination within 7 days prior to enrollment meets the following requirements, as follows:

1) Blood routine: ANC ≥ 1.5 × 10^9/L, Platelet count ≥ 100 × 10^9/L, HGB ≥100 g/L (no blood transfusion or erythropoietin dependence within 14 days); 2) Liver function: TBIL ≤1.5 x ULN; ALT/AST ≤ 5 x ULN; ALP ≤5×ULN; 3) Renal function: Cr ≤1.5×ULN, or creatinine clearance ≥50 mL/min: Urine routine results showed urinary protein < 2+; 4) Coagulation function: INR or PT ≤1.5 x ULN. 9.For female subjects of reproductive age, a urine or serum pregnancy test should be performed and the result is negative 3 days prior to receiving the initial study drug administration.

10. For women of childbearing potential (WOCBP): agreement to refrain from heterosexual intercourse or use contraception.

11. For men: agreement to refrain from heterosexual intercourse or use a condom, and agreement to refrain from donating sperm.

Exclusion Criteria:

  1. Suffered from other malignancies in the past 5 years, excluding cured basal cell carcinoma of the skin, cervical carcinoma in situ and papillary thyroid carcinoma.
  2. Patients requiring elective surgery during the trial.
  3. Patients who cannot take oral drugs, or have conditions that the investigator determines to significantly affect gastrointestinal absorption, such as chronic diarrhea, intestinal obstruction, etc., and are not suitable for treatment.
  4. Patients during pregnancy (positive pregnancy test) or lactation.
  5. Central nervous system metastasis or meningeal metastasis.
  6. Uncontrollable bone metastasis, or patients at risk of fracture, requiring surgery, local radiation therapy.
  7. Patients with active infection requiring systemic anti-infection treatment.
  8. Patients with a history of immunodeficiency, including those who are positive for HIV antibody tests.
  9. Patients with known, active autoimmune diseases.
  10. Patients with uncontrolled active hepatitis B, patients with hepatitis C virus infection (HCV antibody positive).
  11. A history of severe cardiovascular and cerebrovascular diseases, including but not limited to: severe arrhythmia, acute coronary syndrome within 6 months, congestive heart failure, aortic dissection, stroke, and T IA history.
  12. Severe bleeding events occur within half a year, or high bleeding risk factors such as active digestive tract ulcers and esophageal and gastric varices due to liver cirrhosis.
  13. Patients with diabetes who cannot be stably controlled by drugs (including insulin).
  14. Mental or language disorders that prevent communication with the patient;
  15. Patients participating in another clinical trial.
  16. MSI-H/ d MMR without immunotherapy; left colorectum of Ras, Raf wild-type.
  17. The investigator believes that the subject has other serious systemic diseases or other conditions that make him unsuitable for participation in this trial.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: FMT+QL1706+BEVACIZUMAB+XELOX

Participants will receive FMT combined with QL1706+Bevacizumab+XELOX for 6 cycles. If there is no progression of the disease after 6 cycles of the first-line treatment, then patients will enter the maintenance treatment stage. The therapy of maintenance treatment stage was at the discretion of the investigator.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Objective Response Rate (ORR)
Tidsram: up to 24 months

Objective response rate will be assessed by investigators.

up to 24 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Median Progression-Free Survival (mPFS)
Tidsram: up to 24 months

Observation for mPFS will be recorded until the end of follow-up after the start of 1st cycle of treatment.

up to 24 months
Median Overall Survival (mOS)
Tidsram: up to 24 months

The time from the first treatment to death from any cause.

up to 24 months
6-Months Progression-Free Survival Rate (6month-PFS)
Tidsram: up to 6 months

The proportion of patients whose disease did not progress 6 months after treatment

up to 6 months
12-Months Progression-Free Survival Rate (12month-PFS)
Tidsram: up to 12 months

The proportion of patients whose disease did not progress 12 months after treatment

up to 12 months
18-Months Progression-Free Survival Rate (18month-PFS)
Tidsram: up to 18 months

The proportion of patients whose disease did not progress 18 months after treatment

up to 18 months
6-Months overall survival rate(6-Months-OS Rate)
Tidsram: up to 6 months

The proportion of patients who have not died after 6-Months of treatment

up to 6 months
12-Months overall survival rate(12-Months-OS Rate)
Tidsram: up to 12 months

The proportion of patients whose disease did not progress 12 months after treatment

up to 12 months
18-Months overall survival rate(18-Monthsr-OS Rate)
Tidsram: up to 18 months

The proportion of patients who have not died after 18 months of treatment

up to 18 months
Objective Response Rate (ORR) of liver metastases
Tidsram: up to 24 months

Objective response rate will be assessed by investigators.

up to 24 months
Disease Control Rate (DCR)
Tidsram: up to 24 months

The proportion of patients whose tumors achieve a response (CR+PR) and stable disease (SD) after treatment for the minimum duration required.

up to 24 months
Surgical conversion rate
Tidsram: up to 24 months

Proportion of inoperable patients converted to operable.

up to 24 months
Incidence of Adverse events (AEs)
Tidsram: up to 24 months

Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).

up to 24 months
Quality of Life (QoL)
Tidsram: up to 24 months

QoL(quality of life) will be evaluated by EORTC-QLQ-C30.The total score ranges from 0 to 60, with higher scores indicating better quality of life

up to 24 months
The Diversity of Fecal Microbiota
Tidsram: up to 24 months

This will be detected by 16s rRNA sequencing or metagenomes.

up to 24 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

17 april 2025

Primärt slutförande (Beräknad)

1 februari 2027

Avslutad studie (Beräknad)

1 februari 2027

Studieregistreringsdatum

Först inskickad

25 januari 2025

Först inskickad som uppfyllde QC-kriterierna

25 januari 2025

Första postat (Faktisk)

30 januari 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

24 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

22 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • [2025]YLJSA057-01

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera